Related Experiment Video

Updated: May 26, 2026

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
05:21

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection

Published on: August 14, 2019

Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales

R J Pitman1, L J White, M Sculpher

  • 1Oxford Outcomes, Oxford, UK. richard.pitman@oxfordoutcomes.com

Vaccine
|December 20, 2011
PubMed

Insights

Paediatric vaccination significantly reduces influenza burden in England and Wales. Vaccinating children aged 2-18 years can decrease illness, hospitalizations, and deaths by up to 95% through herd immunity.

Area of Science:

  • Epidemiology
  • Public Health
  • Infectious Disease Modeling

Background:

  • Influenza poses a significant annual disease burden, disproportionately affecting the young and elderly.
  • Children are key vectors for influenza virus transmission.
  • Existing vaccination strategies primarily target at-risk groups and the elderly.

Purpose of the Study:

  • To evaluate the population-level impact of implementing a paediatric influenza vaccination program.
  • To assess the effectiveness of vaccinating children aged 2-18 years.
  • To quantify potential reductions in influenza-related morbidity and mortality.

Main Methods:

  • A dynamic transmission model was employed to simulate vaccination scenarios.
  • The model analyzed varying vaccination coverage levels in pre-school and school-aged children.
  • Simulations considered integration with current vaccination strategies for the elderly and at-risk populations.

Main Results:

  • Vaccinating 50% of individuals aged 2-18 years could substantially decrease annual influenza incidence.
  • Paediatric vaccination reduced estimated general practice consultations, hospitalizations, and deaths from influenza A and B by up to 95%.
  • This translates to an average annual reduction of approximately 52,000 consultations, 1500 hospitalizations, and 1200 deaths.

Conclusions:

  • Paediatric influenza vaccination can significantly alleviate the clinical burden of influenza across all age groups in England and Wales.
  • Herd immunity generated by paediatric vaccination offers protection to vulnerable populations, including the young and elderly.
  • Implementing paediatric vaccination is a viable strategy to reduce overall influenza impact.

More Related Videos

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B05:38

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Published on: January 30, 2017

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).